AQST Key Statistics, Chart & Performance
The current stock price of AQST is 3.42 USD. In the past month the price decreased by -44.93%. In the past year, price increased by 10.32%.
AQST Technical Analysis
AQST Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AQST. AQST may be in some trouble as it scores bad on both profitability and health.
AQST Financial Highlights
Over the last trailing twelve months AQST reported a non-GAAP Earnings per Share(EPS) of -0.71. The EPS decreased by -61.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.14% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AQST Forecast & Estimates
15 analysts have analysed AQST and the average price target is 10.77 USD. This implies a price increase of 214.82% is expected in the next year compared to the current price of 3.42.
For the next year, analysts expect an EPS growth of -26.76% and a revenue growth -23.62% for AQST
AQST Ownership
AQST Latest News, Press Relases and Analysis
AQST Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.99 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 20.58 | 514.75B | ||
| MRK | MERCK & CO. INC. | 12.29 | 268.70B | ||
| PFE | PFIZER INC | 7.86 | 143.00B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.84B | ||
| ZTS | ZOETIS INC | 19.66 | 54.92B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.82 | 23.30B | ||
| VTRS | VIATRIS INC | 5.74 | 15.40B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.47 | 12.15B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.79B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.48B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.15B |
Related stock screener links
About AQST
Company Profile
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 142 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. The company has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The firm also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The firm is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Company Info
AQUESTIVE THERAPEUTICS INC
30 Technology Dr
WARREN NEW JERSEY 07059 US
CEO: Keith J. Kendall
Employees: 142
Phone: 19089411900
AQUESTIVE THERAPEUTICS INC / AQST FAQ
What does AQST do?
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 142 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. The company has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The firm also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The firm is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
What is the current price of AQST stock?
The current stock price of AQST is 3.42 USD. The price decreased by -2.56% in the last trading session.
Does AQUESTIVE THERAPEUTICS INC pay dividends?
AQST does not pay a dividend.
How is the ChartMill rating for AQUESTIVE THERAPEUTICS INC?
AQST has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the growth outlook for AQUESTIVE THERAPEUTICS INC?
The Revenue of AQUESTIVE THERAPEUTICS INC (AQST) is expected to decline by -23.62% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of AQST stock?
AQUESTIVE THERAPEUTICS INC (AQST) has a market capitalization of 417.24M USD. This makes AQST a Small Cap stock.
Who owns AQUESTIVE THERAPEUTICS INC?
You can find the ownership structure of AQUESTIVE THERAPEUTICS INC (AQST) on the Ownership tab.